Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01348503 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
A Phase 1 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01348503 is a Phase 1 study that was terminated before completion, run by Indiana University. The registered enrollment target is 5 participants.
The verdict
NCT01348503, a Phase 1 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.
Interventions
- DRUG Lenalidomide
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01348503
The ClinicalTrials.gov registry entry for NCT01348503 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT01348503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01348503 about?
NCT01348503 is a clinical study titled "Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma". The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.
What is the current status of trial NCT01348503?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2011-05. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01348503?
The interventions under investigation include: Lenalidomide (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01348503?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.